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Abstract
Objective—Barrett’s oesophagus is associated with abdominal obesity. Adiponectin is a peptide
that is secreted from adipocytes and circulates in three multimeric forms: low molecular weight
(LMW), middle molecular weight (MMW), and high molecular weight (HMW). The anti-
inflammatory effects of adiponectin are specific to individual multimers, with LMW being most
anti-inflammatory. We postulated that circulating levels of adiponectin and its multimers would be
associated with the risk of Barrett’s oesophagus.
Design—Cross-sectional study.
Setting—Outpatient clinic in North Carolina, USA.
Patients—Cases of Barrett’s oesophagus and controls undergoing upper endoscopy for gastro-
oesophageal reflux disease (GORD).
Main outcome measures—Adjusted odds ratios of plasma adiponectin levels and its
multimers for Barrett’s oesophagus.
Results—There were 112 cases of Barrett’s oesophagus and 199 GORD controls. Total
adiponectin was not associated with Barrett’s oesophagus (3rd tertile vs 1st tertile adjusted odds
ratio (aOR) = 0.88; 95% confidence interval (CI) = 0.44 to 1.78). High levels of LMW adiponectin
were associated with a decreased risk of Barrett’s oesophagus (3rd tertile vs 1st tertile aOR = 0.33;
95% CI, 0.16 to 0.69), and a high LMW/total ratio appeared particularly inversely associated with
Barrett’s oesophagus (3rd tertile vs 1st tertile aOR = 0.27; 95% CI, 0.13 to 0.58).
Conclusions—High levels of LMW adiponectin are associated with a decreased risk of
Barrett’s oesophagus among patients with GORD. Further human studies are required to confirm
these findings, and in vitro studies are needed to understand if there is a mechanism whereby
adiponectin may affect Barrett’s metaplasia.
Oesophageal adenocarcinoma and its accepted precursor, Barrett’s oesophagus, are
associated with obesity, particularly abdominal obesity.1–3 Gastroesophageal reflux disease
(GORD) is well described as a risk factor for both Barrett’s oesophagus and oesophageal
adenocarcinoma.4–6 The effect of obesity on the development of Barrett’s oesophagus and
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oesophageal adenocarcinoma may be due to an effect of obesity promoting GORD. Possible
mechanisms include alterations in the anatomy of the gastro-oesophageal junction and
increased abdominal pressure, or confounding by diet.7–9 However, since obesity is a risk
factor for other cancers for which there are no known structural mechanisms,10 at least some
of the effect of obesity on the risk for Barrett’s oesophagus may be metabolic and mediated
by circulating factors related to obesity.11–13
Adiponectin is a peptide secreted by adipose tissue, whose blood levels are inversely
correlated with obesity and lower in men than women.14 It is involved in regulation of
inflammation,1516 and may suppress carcinogenesis by a number of mechanisms.1718 Low
circulating levels are associated with an increased risk of cancers of the colon, stomach,
prostate, breast, and uterus.17 Specific receptors for adiponectin (AdipoR1 and AdipoR2) are
found in oesophageal mucosa, and adiponectin induces apoptosis in a cell line of
oesophageal adenocarcinoma.19 Adiponectin also inhibits leptin-induced proliferation via
AdipoR1 in cell lines of oesophageal adenocarcinoma.20 In a previous small study, we
found that low plasma levels of adiponectin are associated with an increased risk of Barrett’s
oesophagus among patients undergoing upper endoscopy.13 However, another pilot study
did not detect such a relationship.12
Adiponectin circulates in human blood in three multimeric complexes: trimers (low
molecular weight, LMW), hexamers (middle molecular weight, MMW), and octadecamers
(high molecular weight, HMW).21 Most of the actions of adiponectin on insulin resistance
and coronary artery disease have been attributed to deficiencies in the circulating levels of
the HMW multimer.22–24 In contrast, the three multimers of adiponectin may have
contrasting effects on inflammation. The HMW multimer induces the secretion of the pro-
inflammatory cytokine interleukin 6 (IL6) from human monocytic cells, but the LMW
multimer is anti-inflammatory, suppressing lipopolysaccharide-mediated release of IL6, and
stimulating the secretion of the anti-inflammatory cytokine IL10.25
The specific effects of the multimers on the development of cancer have not yet been well
studied. Low serum levels of HMW adiponectin are associated with the presence of
metastases among normal weight Japanese patients with renal cell carcinoma,26 and with an
increased risk for breast cancer.27 The addition of even sub-physiological levels of HMW
adiponectin to cell lines of prostate and hepatocellular carcinoma suppresses cell
proliferation.28
No prior study has evaluated the effects of the various multimers of adiponectin on the risk
of Barrett’s oesophagus. Our previously published study in a different patient population
was limited to evaluation of total adiponectin levels, and was limited by small sample size
and a matching protocol that resulted in difficulty in fully adjusting for gender in the
analyses. In the current study, we conducted a separate and larger clinic-based, cross-
sectional study of patients with Barrett’s oesophagus compared to patients with GORD and
no Barrett’s oesophagus, and sought to estimate the risk of levels of total adiponectin, and
each of its multimers, for Barrett’s oesophagus. Since adiponectin levels are inversely
associated with insulin levels,2930 and because hyper-insulinaemia might be
carcinogenic,3132 we also assessed whether the relationship of adiponectin with Barrett’s
oesophagus might be confounded by insulin.
METHODS
We performed a clinic-based cross-sectional study comparing levels of adiponectin and its
multimers between subjects with reflux symptoms and Barrett’s oesophagus and subjects
with reflux symptoms but no Barrett’s oesophagus. The primary aim of the original study
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was to evaluate the relationship between obesity, fat distribution, and Barrett’s oesophagus.
Blood specimens had been banked for analysis of future hypotheses such as the present
study.
Subjects
Subjects were recruited from the gastroenterology clinics of the University of North
Carolina between 2002 and 2007, and provided written, informed consent. All enrolled
subjects were between the ages of 18 and 80, and had an upper endoscopy planned for
investigation of GORD symptoms or for surveillance of known Barrett’s oesophagus. Any
patient who underwent endoscopy with a primary or secondary indication of reflux disease
was eligible to participate in the study. All subjects reported classic GORD symptoms
(heartburn, acid regurgitation or waterbrash) to study personnel and had received a physician
diagnosis of GORD. Barrett’s oesophagus cases included both incident and prevalent
diagnoses, and were eligible for inclusion if they had endoscopically evident Barrett’s
oesophagus of any length. For purposes of this study, Barrett’s oesophagus was defined as
the presence of both:
• upward displacement of the squamocolumnar junction noted on endoscopy such
that the junction of squamous and columnar mucosa is no longer at the interface of
the most distal tubular oesophagus and the proximal gastric folds
• intestinal columnar metaplasia, as defined by the presence of columnar epithelium
with goblet cells demonstrated on haematoxylin & eosin staining, in at least one
biopsy specimen from the tubular oesophagus. In equivocal cases, the
documentation of goblet cells by alcian blue staining was considered positive for
intestinalised metaplasia.
The finding of intestinal metaplasia in the oesophagus was necessary, but intestinal
metaplasia without an endoscopic appearance of Barrett’s oesophagus was not sufficient for
inclusion as a case of Barrett’s oesophagus. All subjects who had endoscopic evidence of
Barrett’s oesophagus underwent a standardised biopsy protocol, with jumbo or maximum-
capacity biopsies in four quadrants every 2 cm throughout the length of the endoscopically
abnormal tissue.
Controls for this study consisted of those patients with GORD who did not harbour
endoscopically evident Barrett’s oesophagus. Controls were recruited using the same
protocol as cases.
Exclusion criteria included:
• patients who were unable to read or comprehend the informed consent or written
questionnaires
• patients who were status post-partial or complete oesophageal resection
• patients with prevalent Barrett’s oesophagus who had undergone endoscopic
ablation
• patients found to harbour oesophageal carcinoma on the index endoscopy.
Anthropometry
All body measurements were taken by a trained nurse study coordinator. All subjects were
measured in only thin clothing or a gown. All measurements were entered on a standard data
entry form. The body measurements were obtained as follows:
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• for hip measurements: the average of two successive measurements at the largest
circumference between the waist and thighs while standing
• for waist measurements: the average of two successive measurements at the
umbilicus
• for weight: the subject’s weight, as measured on a balance scale in the clinic
• for height: the subject’s height in inches.
Assays
Blood was drawn after an overnight fast on the morning of the planned endoscopy.
Centrifuge separation of the blood was performed, and samples were aliquoted into 0.1 ml
aliquots. Plasma and serum samples were stored frozen until the completion of enrolment,
then shipped on dry ice to the University of Michigan. Plasma samples were assayed for
adiponectin in the laboratory of one of the investigators (JYK). Available serum samples
were assayed for glucose and insulin in the Chemistry Core of the Michigan Diabetes
Research and Training Center.
Plasma samples were analysed for adiponectin using a commercially available colorimetric
enzyme-linked immunosorbent assay with either no pretreatment, or pretreatment with one
of two proteases that specifically digest either the LMW multimer or the LMW and the
MMW multimers when compared to quantitative western blot analysis (Alpco Diagnostics,
Salem, New Hampshire, USA).33 This provided results for the levels of total, HMW, and
HMW + MMW adiponectin. Each sample was analysed in duplicate. The intra-assay
coefficient of variation for each untreated or pretreated assay is less than 6%;33 however,
since the results for LMW, MMW, and ratio of LMW to total adiponectin are derived from
the results of total, HMW, and HMW + MMW adiponectin, the coefficient of variation for
the derived results are likely greater.
Serum samples were analysed in duplicate for glucose on a Cobas Mira Chemistry Analyzer
(Roche Diagnostics, Indianapolis, Indiana, USA), using reagents from Diagnostic Chemicals
Limited (Oxford, Connecticut, USA). The intra-assay coefficient of variation is 2% at 84
and 283 mg/dl, and inter-assay coefficient of variation is 2.9% at 82 mg/dl and 2.6% at 278
mg/dl. Serum samples were analysed in duplicate for insulin using a double-antibody
radioimmunoassay which utilised a 125I-human insulin tracer (Linco Research, St. Charles,
Missouri, USA), a guinea pig–anti-porcine insulin first antibody (Michigan Diabetes
Research and Training Center, 68.5% cross-reaction to human proinsulin), and a goat–anti-
guinea pig gamma globulin-pegylated second antibody (Antibodies, Davis, California, USA)
and standardised against the Human Insulin International Reference Preparation (National
Institute for Biological Standards and Control). The limit of sensitivity for the assay is 2.1
μU/ml, and inter-assay and intra-assay variabilities are 3.4% and 2.7%, respectively, at 25
μU/ml.
Statistical analysis
Statistical analysis was performed using SAS 9.1. Data were examined for range and logic
inconsistencies. The homeostasis model analysis of insulin resistance (HOMA-IR) was
calculated from the glucose and insulin levels using the formula:34
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Age, body mass index (BMI), waist circumference, hip circumference, and waist/hip ratio
were treated as linear variables after exploring for threshold effects. Subjects were
categorised into tertiles of total plasma adiponectin, multimers of adiponectin, serum insulin,
serum glucose, and HOMA-IR based on the distribution among control subjects. The
associations between continuous variables were examined using Pearson’s correlation.
Comparisons between groups for continuous variables were performed using the t test.
Univariate logistic regression was performed for each variable for the outcome of Barrett’s
oesophagus, and multivariate stepwise forward logistic regression models were created
including adiponectin and each of its multimers. Factors for adjustment were chosen a priori
based on the published risk and protective factors for Barrett’s oesophagus, as limited by the
rule of thumb of requiring 10 outcomes per factor. The factors chosen were age, gender,
race, hiatal hernia, and abdominal obesity. Barrett’s oesophagus appeared to be more closely
associated with waist/hip ratio than the other measures of obesity (waist circumference, hip
circumference, BMI), and so was used in the multivariate models to the exclusion of the
other measures of obesity to avoid colinearity. Effect modification was deemed present if
odds ratios stratified by a categorical variable differed by more than 10%, and was tested for
statistical significance by the Wald χ2 for a cross-product term introduced into the
unstratified logistic regression model. The effects of waist/hip ratio, hiatal hernia,
adiponectin and its multimers appeared to be modified by gender, but did not reach
statistical significance. Since the differences in these stratified and unstratified odds ratios
were greater than the a priori threshold of 10%, but the differences did not reach statistical
significance, models are presented both unstratified by gender (adjusting for age, gender,
waist/hip ratio, hiatal hernia, and race) and stratified by gender (adjusting for the same
factors except race due to smaller numbers in the strata). Since adiponectin levels are
inversely associated with serum insulin levels, and hyperinsulinemia might have direct
effects on carcinogenesis, the possibility of confounding was assessed by further adjusting
the models for insulin levels or HOMA-IR.
RESULTS
Baseline characteristics
A total of 536 subjects were potentially eligible for this study and all of these were screened
for eligibility. Of subjects with Barrett’s oesophagus, 137 were found to be eligible for the
study, and 112 (82%) participated. Of control subjects, 280 subjects were eligible for the
study, and 199 subjects participated (71%). The most common reason for declining
participation was unwillingness to undergo an additional phlebotomy. Because of the cross-
sectional nature of the study, all subjects consenting to participation completed the study.
The baseline characteristics of the subjects are presented in table 1. Patients with Barrett’s
oesophagus were older, and there was a higher proportion of men and whites than GORD
controls. There was no difference in BMI between groups, but cases had larger average
waist circumference and smaller hip circumference. Cases included a higher proportion with
hiatal hernia. There was no difference in total plasma adiponectin (sum of all multimers),
but cases of Barrett’s oesophagus had higher mean HMW adiponectin, and lower mean
MMW and LMW adiponectin. The average ratio of LMW to total adiponectin was lower in
Barrett’s oesophagus cases than in GORD controls. The distributions of the LMW levels and
of the LMW to total adiponectin ratios are displayed stratified by case/control status and
gender in fig 1 and 2.
Among controls, plasma levels of total and LMW adiponectin were weakly and inversely
correlated with BMI in both men (rho = −0.27, p = 0.03, and rho = −0.11, p = 0.37 for total
and LMW, respectively) and women (rho = −0.37, p<0.0001, and rho = −0.22, p = 0.01 for
total and LMW, respectively), and inversely correlated with waist/hip ratio among women
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only (rho = −0.24, p = 0.01, and rho = −0.10, p = 0.26 for total and LMW, respectively).
Similar gender-specific inverse correlations were found among cases, between HMW or
MMW adiponectin and BMI or waist/hip ratio, and between multimers and waist
circumference. The ratio of LMW to total adiponectin was not correlated with either BMI or
waist/hip ratio among controls or among male cases, but was moderately correlated with
BMI (rho = 0.41, p = 0.01) and waist/hip ratio (rho = 0.51, p = 0.001) among female cases.
Female control subjects had higher total levels of adiponectin than male controls (6.39 μg/
ml vs 5.13, p = 0.002), and higher levels of HMW (2.68 μg/ml vs 2.00, p = 0.007), and
MMW forms (1.45 μg/ml vs 1.13, p = 0.02), but no difference was detected in levels of
LMW (2.26 μg/ml vs 2.01, p = 0.11) or the ratio of LMW to total adiponectin (0.38 vs 0.41,
p = 0.19). Adiponectin levels in non-obese GORD controls are presented in table 2.
Association between adiponectin and Barrett’s oesophagus
The total plasma level of adiponectin was not associated with the risk of Barrett’s
oesophagus compared to GORD controls (adjusted odds ratio (aOR) 3rd tertile vs 1st tertile,
aOR = 0.88; 95% CI, 0.44 to 1.78) (table 3). However, the highest tertile of LMW
adiponectin was associated with one-third the risk of Barrett’s oesophagus, adjusting for
waist/hip ratio, gender, hiatal hernia, age, and race (3rd vs 1st tertiles aOR = 0.33; 95% CI,
0.16 to 0.69). The ratio of LMW to total adiponectin was most closely inversely associated
with the risk of Barrett’s oesophagus (3rd vs 1st tertiles aOR = 0.27; 95% CI, 0.13 to 0.58).
In contrast, higher levels of HMW adiponectin were marginally associated with an increased
risk of Barrett’s oesophagus (3rd vs 1st tertiles aOR = 1.96; 95% CI, 0.96 to 4.03). Full
logistic regression models adjusting for waist circumference rather than waist/hip resulted in
similar point estimates (data not shown).
Analyses stratified by gender
The effect of a number of variables (waist/hip ratio, hiatal hernia, adiponectin and its
multimers) appeared to be modified by gender; therefore, analyses were also performed
stratifying by gender (table 4). Although subject numbers in some cells are small, this
analysis revealed a possibly stronger association of low levels of LMW adiponectin with
Barrett’s oesophagus among women than among men. Although the adjusted odds ratio was
less than 0.5 among men, the association between LMW adiponectin levels and Barrett’s
oesophagus lost statistical significance, perhaps due to small sample size in the stratified
analyses. However, the association of low LMW/total adiponectin ratio with Barrett’s
oesophagus remained strong and statistically significant among both genders. This
association also appeared stronger among women than among men.
Because adiponectin levels are affected by menopause,29 we performed analyses in 107 of
the 169 women in whom menstrual status was known. Adjusting for age, post-menopausal
status was not associated with Barrett’s oesophagus (OR = 1.82; 95% CI, 0.37 to 8.90).
There were only three pre-menopausal women with Barrett’s oesophagus, limiting the
power of the analysis. Nonetheless, the association of adiponectin multimers with Barrett’s
oesophagus among women appeared similar after adjustment for menopausal status in
addition to adjustments for age, hiatal hernia, and waist/hip ratio (LMW 3rd tertile vs 1st
tertile of aOR = 0.20; 95% CI, 0.04 to 0.99; LMW/Total 3rd tertile vs 1st tertile of aOR =
0.33; 95% CI, 0.07 to 1.5).
Assessment for confounding by hyperinsulinaemia
Among controls, plasma levels of total and LMW adiponectin were weakly and inversely
correlated with serum levels of insulin (rho = −0.31, p<0.0001, and rho = −0.20, p = 0.006
for total and LMW, respectively), and with the HOMA-IR (rho = −0.21, p = 0.005, and rho
= −0.16, p = 0.04 for total and LMW, respectively), but not with serum glucose levels (rho =
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−0.09, p = 0.24, and rho = −0.05, p = 0.52 for total and LMW, respectively). However, the
ratio of LMW to total adiponectin was not correlated with insulin (rho = 0.12, p = 0.12) or
with HOMA-IR (rho = 0.05, p = 0.53). Similar correlations were observed across genders.
Among cases of Barrett’s oesophagus, there appeared to be closer inverse correlation
between total adiponectin with HOMA-IR (rho = −0.29, p = 0.0037), and also a weakly
positive correlation between the ratio of LMW to total adiponectin with insulin (rho = 0.20,
p = 0.044) and with HOMA-IR (rho = 0.17, p = 0.08).
Serum insulin levels were not associated with Barrett’s oesophagus (3rd tertile vs 1st tertile
aOR = 0.87; 95% CI, 0.41 to 1.8), adjusting for gender, age, hiatal hernia, race, and waist/
hip ratio. Neither were serum glucose levels (3rd tertile vs 1st tertile aOR = 1.0; 95% CI,
0.49 to 2.1) or HOMA-IR (3rd tertile vs 1st tertile aOR = 0.63; 95% CI, 0.29 to 1.3).
Multivariate logistic regression was repeated, adjusting for insulin in addition to gender, age,
hiatal hernia, race, and waist/hip ratio. Higher levels of LMW adiponectin remained
inversely associated with Barrett’s oesophagus in this model (3rd tertile vs 1st tertile aOR =
0.35; 95% CI, 0.16 to 0.77). Adjusting for HOMA-IR rather than insulin resulted in nearly
identical estimates (3rd tertile vs 1st tertile aOR = 0.35; 95% CI, 0.16 to 0.76). Likewise, the
ratio of LMW to total adiponectin remained inversely associated with Barrett’s oesophagus
in models further adjusted for insulin (3rd tertile vs 1st tertile aOR = 0.20; 95% CI, 0.084 to
0.46) or HOMA-IR (3rd tertile vs 1st tertile aOR = 0.21; 95% CI, 0.092 to 0.49).
DISCUSSION
We performed a clinic-based study estimating the association between circulating levels of
multimers of adiponectin and the presence of Barrett’s oesophagus. We did not find any
association between the total level of adiponectin and the presence of Barrett’s oesophagus,
but did find that higher levels of the LMW multimers (trimers) of adiponectin were
associated with one-third the risk of Barrett’s oesophagus. These effects may be stronger
among women than among men, but we did not find a statistically significant interaction
between adiponectin multimers and gender.
If adiponectin levels do influence the risk of Barrett’s oesophagus, what might be the
mechanism? Adiponectin can bind to growth factors, thereby inhibiting the growth factors’
interaction with their cell membrane receptors.35 Adiponectin activates the 5′-AMP-
activated protein kinase (AMPK) pathway, thereby suppressing cell proliferation, perhaps in
part by regulating p21 and p53.18 Adiponectin also suppresses expression of cyclin D1,
possibly via regulation of the β-catenin–Wnt pathway.18 Cyclin D1, Wnt and p53 are
involved in neoplastic progression in Barrett’s oesophagus.36–38 Indeed, adiponectin induces
apoptosis in a cell line of oesophageal adenocarcinoma,19 and inhibits leptin-induced
proliferation in cell lines of oesophageal adenocarcinoma.20 However, most of these studies
have not attempted to distinguish the effects of the various multimers, and the effect of
adiponectin on the metaplastic event has not been directly studied in vitro. Since Barrett’s
metaplasia is believed to be an aberrant response in the setting of erosive oesophagitis,39 an
attractive hypothesis is that normal levels of circulating LMW adiponectin are sufficient to
suppress the inflammatory response to GORD,25 or guide the healing response toward
regeneration of squamous mucosa. For instance, LMW adiponectin might suppress the local
expression of IL6 in oesophageal mucosa.25 IL6 expression has been shown to be increased
in the epithelium of Barrett’s oesophagus.40 In the setting of low levels of LMW
adiponectin, the response to GORD might be directed toward a more exuberant oesophagitis
and/or metaplasia into intestinal epithelium. Our finding that a low ratio of LMW to total
adiponectin may be particularly associated with Barrett’s oesophagus could be explained by
the opposing effects of different multimers on inflammation.25 Although high LMW or high
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LMW to total adiponectin ratio appeared most strongly protective of Barrett’s oesophagus in
the current study, a positive but weaker association was observed between high levels of
HMW adiponectin and Barrett’s oesophagus. It is not clear whether any effect of
adiponectin on Barrett’s oesophagus is mediated by protection by LMW adiponectin,
promotion by HMW adiponectin or both.
Adiponectin is one of many circulating factors associated with obesity, and the observed
effect of LMW adiponectin may be confounded by any or many of these factors that were
not measured in this study. For instance, IL6 downregulates adipocyte expression of
adiponectin,41 and circulating IL6 or other cytokines might instead be responsible for
Barrett’s metaplasia. Total adiponectin is inversely associated with insulin, and
hyperinsulinaemia could instead be the causative factor related to Barrett’s oesophagus.2930
However, the insulin-sensitising effect of adiponectin appears to be specifically due to the
HMW multimer.22 We found no association between serum insulin levels, or between an
estimate of insulin resistance, and the presence of Barrett’s oesophagus. Further adjusting
for insulin levels or insulin resistance did not appreciably alter the observed association
between LMW adiponectin and Barrett’s oesophagus. Menopause is associated with an
increase in total adiponectin,29 and studies of the association of adiponectin with breast
cancer risk have generally found an inverse association only among post-menopausal
women.42–44 The stronger effect of LMW adiponectin on Barrett’s oesophagus that we
observed among women might be due to interactions with sex hormones, or an
epiphenomenon. Unfortunately, we had too few pre-menopausal women with Barrett’s
oesophagus (n = 3) to draw any conclusions regarding an interaction between menopausal
status and adiponectin multimers for the risk of Barrett’s oesophagus.
The results of this study differed from our pilot study in a different population finding
evidence for an association between Barrett’s oesophagus and low levels of total
adiponectin.13 This may have been due to differences in subject populations or the assay
used to measure adiponectin. Also, the association in that study with total adiponectin
became statistically insignificant after adjusting for waist/hip ratio. Our current null finding
is consistent with a small pilot study performed by another group.12 However, unlike the
present work, neither of these previous studies measured levels of the specific multimers.
Although the present study involved more than 300 subjects, certain stratified analyses were
limited by small numbers. The present study is limited by the potential for unmeasured
confounders such as dietary habits. A diet high in whole grain cereals is positively correlated
with circulating levels of total adiponectin, but to our knowledge dietary habits have not
been correlated with circulating levels of the adiponectin multimers.45 Other potential
unmeasured confounders include physical activity, Helicobacter pylori infection, and the use
of non-steroidal anti-inflammatory drugs. Despite our attempts to control for multiple
factors, there may have also been residual confounding by obesity or GORD. The present
study did not have access to adiponectin levels in a control group without GORD; levels of
adiponectin and its multimers in our GORD control group were higher than those found in
non-obese men without insulin resistance, but these differences may be due to other
differences in study populations or assays.25 Comparing adiponectin levels to a non-obese
population without GORD and without Barrett’s oesophagus could yield further
understanding of the mechanism of the effect of adiponectin on Barrett’s oesophagus.
Another limitation is the inclusion of both incident and prevalent cases of Barrett’s
oesophagus, and the clinic-based nature of the study. While a population-based design
would be preferable, the costs associated with recruiting subjects with GORD, then
identifying over 100 Barrett’s oesophagus cases from this population were prohibitive. The
strengths of our study include the rigorous data collection by trained research assistants, the
prospective nature of our data collection and specimen banking, the low likelihood of
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misclassification due to the rigorous biopsy protocol, and the measurement of body
anthropomorphic measurements on-site by trained study staff.
In summary, we found a strong inverse relationship between circulating levels of LMW
adiponectin and the presence of Barrett’s oesophagus among patients with GORD. If noted
in other studies, this finding has implications both for models of pathogenesis of Barrett’s
oesophagus, as well as for potential use as a biomarker of disease. Further human studies are
required to confirm our findings, and in vitro studies are needed to understand if there is a
mechanism whereby adiponectin may promote Barrett’s metaplasia.
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Box-plot of low molecular weight adiponectin. Each box-plot displays the 10th, 25th, 50th,
75th, and 90th percentiles of low molecular weight (LMW) adiponectin in cases of Barrett’s
oesophagus and GORD controls, stratified by gender.
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Box-plot of ratio of low molecular weight to total adiponectin. Each box-plot displays the
10th, 25th, 50th, 75th, and 90th percentiles of the ratio of low molecular weight (LMW) to
total adiponectin in cases of Barrett’s oesophagus and GORD controls, stratified by gender.
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Table 1
Baseline characteristics
Barrett’s oesophagus cases GORD controls
p ValueMean (SD) or number (%) Mean (SD) or number (%)
Number of subjects 112 199
Age (years) 57.4 (11.3) 50.7 (13.3) <0.0001
Gender <0.0001
 Male 73 (65) 69 (35)
 Female 39 (35) 130 (65)
Race 0.003
 White 106 (95) 160 (80)
 Black 4 (4) 30 (15)
 Other 2 (2) 9 (5)
Smoking status (ever smokers) 53 (50) 95 (48) 0.68
BMI (kg/m2) 28.2 (5.1) 28.7 (6.2) 0.46
Waist circumference (cm) 94.3 (15.2) 91.6 (16.3) 0.18
Hip circumference (cm) 101.7 (12.7) 104.2 (14.7) 0.15
Waist/hip ratio 0.93 (0.10) 0.88 (0.09) <0.0001
Hiatal hernia 60 (57) 74 (38) 0.002
Adiponectin
 Total (μg/ml) 6.03 (3.32) 5.95 (2.87) 0.83
 High molecular weight (μg/ml) 3.09 (2.41) 2.44 (1.81) 0.01
 Middle molecular weight (μg/ml) 1.13 (0.82) 1.34 (1.08) 0.06
 Low molecular weight (μg/ml) 1.80 (1.09) 2.17 (1.08) 0.004
 Low molecular weight/total ratio 0.33 (0.13) 0.39 (0.16) 0.0002
Results are given as the mean (SD) or number (%).
GORD, gastro-oesophageal reflux disease.
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Table 2
Plasma adiponectin in non-obese GORD controls
Males mean (SD) Females mean (SD) p Value
Number of subjects 47 59
Total (μg/ml) 5.31 (2.43) 6.32 (2.25) 0.03
High molecular weight (μg/ml) 2.14 (1.63) 2.51 (1.38) 0.21
Middle molecular weight (μg/ml) 1.11 (0.73) 1.42 (0.83) 0.05
Low molecular weight (μg/ml) 2.06 (0.95) 2.39 (1.12) 0.10
Low molecular weight/total ratio 0.41 (0.15) 0.39 (0.15) 0.63
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Table 3
Plasma adiponectin and Barrett’s oesophagus
No. of Barrett’s oesophagus/no. of GORD OR (95% CI)*
OR (95% CI)†
Adjusted for waist/hip ratio
Total adiponectin
 1st tertile 44/67 1.00 (reference) 1.00 (reference)
 2nd tertile 32/66 0.59 (0.30 to 1.15) 0.65 (0.32 to 1.30)
 3rd tertile 36/66 0.87 (0.45 to 1.66) 0.88 (0.44 to 1.78)
HMW adiponectin
 1st tertile 29/67 1.00 (reference) 1.00 (reference)
 2nd tertile 35/66 1.13 (0.58 to 2.23) 1.02 (0.50 to 2.08)
 3rd tertile 48/66 1.81 (0.92 to 3.53) 1.96 (0.96 to 4.03)
MMW adiponectin
 1st tertile 42/67 1.00 (reference) 1.00 (reference)
 2nd tertile 43/66 0.95 (0.51 to 1.77) 0.96 (0.50 to 1.85)
 3rd tertile 27/66 0.73 (0.370 to 1.43) 0.82 (0.40 to 1.68)
LMW adiponectin
 1st tertile 52/67 1.00 (reference) 1.00 (reference)
 2nd tertile 41/66 0.88 (0.48 to 1.60) 0.84 (0.45 to 1.58)
 3rd tertile 19/66 0.36 (0.18 to 0.72) 0.33 (0.16 to 0.69)
LMW/total
 1st tertile 54/66 1.00 (reference) 1.00 (reference)
 2nd tertile 42/66 0.63 (0.35 to 1.16) 0.61 (0.32 to 1.15)
 3rd tertile 16/67 0.30 (0.15 to 0.62) 0.27 (0.13 to 0.58)
*
Odds ratios are adjusted for gender, hiatal hernia, age and race.
†
Odds ratios are adjusted for waist/hip ratio, gender, hiatal hernia, age and race.
CI, confidence interval; GORD, gastro-oesophageal reflux disease; OR, odds ratio.
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Table 4
Plasma adiponectin and Barrett’s oesophagus, stratified by gender
Men Women
No. of Barrett’s oesophagus/no. of
GORD (n = 73/69) OR (95% CI)
No. of Barrett’s oesophagus/no. of
GORD (n = 39/130) OR (95% CI)
Total adiponectin
 1st tertile 34/33 1.00 (reference) 11/44 1.00 (reference)
 2nd tertile 21/22 0.72 (0.29 to 1.79) 10/34 0.60 (0.20 to 1.84)
 3rd tertile 18/14 0.93 (0.35 to 2.48) 18/52 0.90 (0.32 to 2.52)
HMW adiponectin
 1st tertile 22/32 1.00 (reference) 7/35 1.00 (reference)
 2nd tertile 27/21 1.64 (0.68 to 3.96) 8/45 0.47 (0.14 to 1.67)
 3rd tertile 24/16 1.72 (0.65 to 4.53) 24/50 1.81 (0.63 to 5.16)
MMW adiponectin
 1st tertile 33/28 1.00 (reference) 9/39 1.00 (reference)
 2nd tertile 27/24 0.87 (0.37 to 2.03) 16/42 1.26 (0.45 to 3.52)
 3rd tertile 13/17 0.65 (0.23 to 1.82) 14/49 1.12 (0.40 to 3.18)
LMW adiponectin
 1st tertile 37/25 1.00 (reference) 15/42 1.00 (reference)
 2nd tertile 23/23 0.85 (0.35 to 2.09) 18/43 0.76 (0.30 to 1.92)
 3rd tertile 13/21 0.44 (0.17 to 1.16) 6/45 0.23 (0.07 to 0.77)
LMW/total
 1st tertile 31/18 1.00 (reference) 23/48 1.00 (reference)
 2nd tertile 30/27 0.64 (0.26 to 1.55) 12/39 0.59 (0.24 to 1.48)
 3rd tertile 12/24 0.32 (0.12 to 0.88) 4/43 0.20 (0.06 to 0.69)
Odds ratios are adjusted for waist/hip ratio, hiatal hernia, and age.
GORD, gastro-oesophageal reflux disease; HMW, high molecular weight (adiponectin); CI, confidence interval; LMW, low molecular weight;
MMW, middle molecular weight; OR, odds ratio.
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